{
  "docId": "019de076-f497-7249-9bc1-6e417e62b814",
  "docSlug": "fb4563ff56b082126dc8200b1dba24d8",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 23 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 23,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes a process diagram for ex-vivo biopsy treatment and two dose-response curves for IL-6 and IL-8 inhibition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f497-7249-9bc1-6e417e62b814/22",
  "deckHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814",
  "deckJsonHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814.json",
  "deckAnchorHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.72,
        "y": 0.33
      },
      "kind": "chart",
      "text": "IL-8 dose-response curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b70b92f-581e-40f9-aced-567b8b702f6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.48,
        "y": 0.33
      },
      "kind": "chart",
      "text": "IL-6 dose-response curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48fe07af-7c5e-43ee-aecd-6f5ce9c402a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.48,
        "y": 0.65
      },
      "kind": "diagram",
      "text": "UC endoscopic biopsy -> Colonic mucosa organ culture & compound treatment -> Inflammatory cytokine measurement",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "037090b0-ff0a-45d4-9008-5d7bf2be7def",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "PDE10 was discovered as a novel target for IBD using the Benevolent Platform and validated experimentally using ex vivo biopsies from UC patients. BEN-8744 was selected as a candidate in August 2021 as a highly potent and selective PDE10 inhibitor. In vitro and in vivo PK characterisation demonstrated strong cross-species IVIVC. Low predicted human dose based on cross-species allometric scaling. Phase 1a SAD, MAD, Food Effect study in healthy volunteers completes Q1 24",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae18313e-c320-4f3b-982d-793e20382ee7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BEN-8744, a highly potent and selective PDE10 inhibitor has entered Phase 1a clinical development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8035bf3-a320-4451-baf9-03458b0fb6f4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 17,
      "beatId": "e47af714-75e9-499c-97df-2a13daa68262",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "Appendix and closing ask",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b0e19ace-ba0d-475a-81b8-bb29008de35f",
      "evidence": "The deck's overall narrative and key takeaways",
      "position": 1,
      "objective": "Communicating the why, how, and what of BenevolentAI's AI-driven drug discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}